PARP2 Inhibitors
2 drugsAbout PARP2
PARP2, or Poly (ADP-ribose) polymerase 2, is a protein involved in DNA repair, genomic stability, and apoptosis. It functions by catalyzing the addition of ADP-ribose units to target proteins, a process crucial for DNA damage response.
PARP2 is a compelling drug target, particularly in oncology, due to its role in DNA repair. Currently, there is no genetic evidence directly linking PARP2 to specific diseases.
Two FDA-approved drugs, LYNPARZA (AstraZeneca) and TALZENNA (Pfizer), target PARP2 in oncology. Both drugs are small molecules that inhibit PARP2 to disrupt DNA repair in cancer cells.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
Human Genetic Evidence
There is currently no genetic evidence data available for PARP2.
Absence of genetic evidence suggests higher risk of failure in clinical trials.
Evidence Across Diseases
1 totalGWAS and other genetic studies link PARP2 to 1 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for PARP2 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
AstraZeneca and Pfizer are the only two companies with approved PARP2-targeting drugs.
High market concentration suggests significant barriers to entry for new competitors.
Drug Modality Landscape
Modalities
Routes of Administration
PARP2 is amenable to small molecule drugs, with oral options available for convenient dosing.
Consider exploring alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
Clinical Trials 440 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 170 | 74 | 24 | 71 | 76% |
| Phase 2 | 219 | 58 | 37 | 121 | 61% |
| Phase 3 | 43 | 16 | 3 | 24 | 84% |
| Phase 4 | 8 | 4 | 1 | 3 | 80% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved PARP2 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PARP2. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2014 - 2018)
The first PARP2-targeting drug was approved in 2014, and the most recent in 2018.
The relatively short approval span indicates potential for further innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 386 clinical trials targeting PARP2.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities